Immune cells Tailor-Made to attack pancreatic cancer enter first human test
NCT ID NCT06549751
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new therapy called MT-601, which uses a patient's own immune T-cells trained to recognize multiple cancer-related targets. It is for people with advanced pancreatic cancer that cannot be removed by surgery or has spread. The study will check safety and whether the cells can shrink tumors, with up to 38 participants receiving different doses alongside chemotherapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Patient-derived multi-tumor-associated antigen specific T cells (MT-601)
- What this could lead to
- If it works, this could point toward a new treatment option for advanced pancreatic cancer that uses a patient's own immune cells to fight the tumor.
- What could go wrong
- This is a very early Phase 1 trial with only 38 participants, so safety and effectiveness are not yet proven. The therapy may not shrink tumors or could cause serious side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREAS CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The University of Texas MD Anderson
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug immune attack shrink Hard-to-Treat pancreatic tumors?
- Can a pill rouse the immune system against pancreatic cancer?
- Can a new ultrasound technique spot hidden pancreatic cancers earlier?
- A sound wave that could expose hidden pancreatic cancer?
- Can three common drugs boost chemotherapy against pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?